~~<i id='5F54D76B9D'><strike id='5F54D76B9D'><tt id='5F54D76B9D'><pre id='5F54D76B9D'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-06 08:11:50 Page View：3

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Private equity could exacerbate cardiology's overuse problem, experts fear
Next article： What does generative AI mean for health care? We asked experts

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

How to make the FDA’s new prescription one

AdobePatientsoftenasktwoquestionsabouteverymedicaltreatment:Willithelpme?Willithurtme?TheFoodandDrug

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

What to make of Biden’s latest efforts on cancer research

PresidentBidenspeaksontheCancerMoonshotinitiativeattheJohnF.KennedyLibraryin2022.EvanVucci/APWASHING